
Arnold S Monto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8625972/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clinical Infectious Diseases, 2023, 76, e460-e468.	5.8	9
2	Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015–2016 to 2017–2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Clinical Infectious Diseases, 2022, 74, 1329-1337.	5.8	7
3	Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment. Clinical Infectious Diseases, 2022, 74, 532-540.	5.8	25
4	Clinical Influenza Testing Practices in Hospitalized Children at United States Medical Centers, 2015-2018. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 5-8.	1.3	2
5	Distinct influenza surveillance networks and their agreement in recording regional influenza circulation: Experience from Southeast Michigan. Influenza and Other Respiratory Viruses, 2022, 16, 521-531.	3.4	6
6	The 2009 Pandemic H1N1 Hemagglutinin Stalk Remained Antigenically Stable after Circulating in Humans for a Decade. Journal of Virology, 2022, 96, e0220021.	3.4	0
7	Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clinical Infectious Diseases, 2022, 75, S159-S166.	5.8	13
8	Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016–2017 and 2017–2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Journal of Infectious Diseases, 2021, 223, 2062-2071.	4.0	15
9	Effects of Prior Season Vaccination on Current Season Vaccine Effectiveness in the United States Flu Vaccine Effectiveness Network, 2012–2013 Through 2017–2018. Clinical Infectious Diseases, 2021, 73, 497-505.	5.8	15
10	Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015–2018. Clinical Infectious Diseases, 2021, 73, 386-392.	5.8	41
11	Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults—United States, 2015–2017. Clinical Infectious Diseases, 2021, 72, 995-1003.	5.8	29
12	Home collection of nasal swabs for detection of influenza in the Household Influenza Vaccine Evaluation Study. Influenza and Other Respiratory Viruses, 2021, 15, 227-234.	3.4	14
13	Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses. Journal of Infectious Diseases, 2021, 224, 49-59.	4.0	26
14	Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators. Clinical Infectious Diseases, 2021, 73, 2240-2247.	5.8	18
15	Effectiveness of Influenza Vaccines in the HIVE Household Cohort Over 8 Years: Is There Evidence of Indirect Protection?. Clinical Infectious Diseases, 2021, 73, 1248-1256.	5.8	8
16	Immune-mediated attenuation of influenza illness after infection: opportunities and challenges. Lancet Microbe, The, 2021, 2, e715-e725.	7.3	29
17	Waning Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2015–2016 to 2018–2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network. Clinical Infectious Diseases, 2021, 73, 726-729.	5.8	32
18	Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017. Clinical Infectious Diseases, 2021, 72, 1147-1157.	5.8	22

#	Article	IF	CITATIONS
19	Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018–2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network. Journal of Infectious Diseases, 2021, 224, 151-163.	4.0	13
20	Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019–2020. Journal of Infectious Diseases, 2021, 224, 813-820.	4.0	30
21	Lessons From Influenza Pandemics of the Last 100 Years. Clinical Infectious Diseases, 2020, 70, 951-957.	5.8	57
22	Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS). Clinical Infectious Diseases, 2020, 71, 1186-1194.	5.8	16
23	Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018–2019 Season. Journal of Infectious Diseases, 2020, 221, 8-15.	4.0	150
24	Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. Nature Communications, 2020, 11, 4566.	12.8	43
25	Reply. Journal of Infectious Diseases, 2020, 222, 1579-1579.	4.0	0
26	Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance, 2020, 25, .	7.0	309
27	Coronavirus Occurrence and Transmission Over 8 Years in the HIVE Cohort of Households in Michigan. Journal of Infectious Diseases, 2020, 222, 9-16.	4.0	128
28	Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans. Journal of Virology, 2019, 93, .	3.4	33
29	HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. BMC Infectious Diseases, 2019, 19, 453.	2.9	23
30	Comparison of a frailty short interview to a validated frailty index in adults hospitalized for acute respiratory illness. Vaccine, 2019, 37, 3849-3855.	3.8	5
31	Social patterning of acute respiratory illnesses in the Household Influenza Vaccine Evaluation (HIVE) Study 2014–2015. Epidemiology and Infection, 2019, 147, e185.	2.1	4
32	Data resource profile: Household Influenza Vaccine Evaluation (HIVE) Study. International Journal of Epidemiology, 2019, 48, 1040-1040g.	1.9	14
33	Antibodies Against Egg- and Cell-Grown Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017–2018 Influenza Season. Journal of Infectious Diseases, 2019, 219, 1904-1912.	4.0	37
34	Effects of Influenza Vaccination in the United States During the 2017–2018 Influenza Season. Clinical Infectious Diseases, 2019, 69, 1845-1853.	5.8	218
35	Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection. Journal of Infectious Diseases, 2019, 219, S75-S80.	4.0	75
36	Effects of Sequential Influenza A(H1N1)pdm09 Vaccination on Antibody Waning. Journal of Infectious Diseases, 2019, 220, 12-19.	4.0	12

#	Article	IF	CITATIONS
37	Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population. Vaccine, 2019, 37, 1284-1292.	3.8	14
38	Influenza Vaccine Effectiveness Against Hospitalization in Fully and Partially Vaccinated Children in Israel: 2015–2016, 2016–2017, and 2017–2018. Clinical Infectious Diseases, 2019, 69, 2153-2161.	5.8	23
39	1642. Comparing Viral Respiratory Infections Between Children Who Do and Do Not Attend Child Care. Open Forum Infectious Diseases, 2019, 6, S599-S599.	0.9	0
40	2734. Lack of Influence of Early Exposure to Influenza A(H3N2) Viruses on Vaccine Effectiveness Against A(H3N2)-Associated Illness in US Children <18 Years, 2016–2018. Open Forum Infectious Diseases, 2019, 6, S962-S962.	0.9	0
41	2760. Accounting for Vaccination History in Estimates of Current Season Vaccine Effectiveness in the US Flu VE Network, 2012–2013 Through 2017–2018. Open Forum Infectious Diseases, 2019, 6, S973-S973.	0.9	0
42	900. Effect of Influenza Vaccine Priming on Current Season Vaccine Effectiveness among Children and Adolescents, US Flu VE Network 2014–2015 Through 2017–2018. Open Forum Infectious Diseases, 2019, 6, S27-S27.	0.9	0
43	Influenza Vaccine Effectiveness in the United States During the 2016–2017 Season. Clinical Infectious Diseases, 2019, 68, 1798-1806.	5.8	90
44	Prevention of Influenza Hospitalization Among Adults in the United States, 2015–2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Journal of Infectious Diseases, 2019, 220, 1265-1275.	4.0	59
45	Hospitalization following outpatient medical care for influenza: <scp>US</scp> influenza vaccine effectiveness network, 2011â€12—2015â€16. Influenza and Other Respiratory Viruses, 2019, 13, 133-137.	3.4	4
46	Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011–2017. Clinical Infectious Diseases, 2019, 68, 1616-1622.	5.8	9
47	Maximum likelihood estimation of influenza vaccine effectiveness against transmission from the household and from the community. Statistics in Medicine, 2018, 37, 970-982.	1.6	9
48	Human coronaviruses and other respiratory infections in young adults on a university campus: Prevalence, symptoms, and shedding. Influenza and Other Respiratory Viruses, 2018, 12, 582-590.	3.4	39
49	Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study. Influenza and Other Respiratory Viruses, 2018, 12, 267-278.	3.4	73
50	Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clinical Infectious Diseases, 2018, 66, 1492-1500.	5.8	115
51	Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons—United States, 2011–2016. Clinical Infectious Diseases, 2018, 66, 1035-1041.	5.8	23
52	The risk of lower respiratory tract infection following influenza virus infection: A systematic and narrative review. Vaccine, 2018, 36, 141-147.	3.8	53
53	995. Effectiveness of Influenza Vaccine for Prevention of Influenza-Associated Hospitalizations Among High-Risk Adults in the United States, 2015–2016. Open Forum Infectious Diseases, 2018, 5, S296-S296.	0.9	0
54	988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010–2018. Open Forum Infectious Diseases, 2018, 5, S292-S292.	0.9	0

#	Article	IF	CITATIONS
55	Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI): study protocol. BMC Infectious Diseases, 2018, 18, 550.	2.9	8
56	997. Protection of Unvaccinated Individuals by Influenza Vaccine Coverage of Household Contacts. Open Forum Infectious Diseases, 2018, 5, S296-S297.	0.9	0
57	Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain. Vaccine, 2018, 36, 4095-4101.	3.8	18
58	Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. Journal of Infectious Diseases, 2018, 218, 189-196.	4.0	43
59	Sera from Individuals with Narrowly Focused Influenza Virus Antibodies Rapidly Select Viral Escape Mutations <i>In Ovo</i> . Journal of Virology, 2018, 92, .	3.4	19
60	Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Network Open, 2018, 1, e180243.	5.9	146
61	Prior-Season Vaccination and Risk of Influenza During the 2014–2015 Season in the United States. Journal of Infectious Diseases, 2017, 216, 284-285.	4.0	1
62	Application of an Individual-Based Transmission Hazard Model for Estimation of Influenza Vaccine Effectiveness in a Household Cohort. American Journal of Epidemiology, 2017, 186, 1380-1388.	3.4	10
63	Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30–October 1, 2015. Vaccine, 2017, 35, 2279-2287.	3.8	27
64	The Doctrine of Original Antigenic Sin: Separating Good From Evil. Journal of Infectious Diseases, 2017, 215, 1782-1788.	4.0	131
65	The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014–2015 Influenza Vaccine. Clinical Infectious Diseases, 2017, 65, 1644-1651.	5.8	36
66	Respiratory syncytial virus hospitalization in middle-aged and older adults. Journal of Clinical Virology, 2017, 96, 37-43.	3.1	51
67	Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season. New England Journal of Medicine, 2017, 377, 534-543.	27.0	240
68	Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness. Journal of Infectious Diseases, 2017, 215, 841-843.	4.0	12
69	Moving Toward Improved Influenza Vaccines. Journal of Infectious Diseases, 2017, 215, 500-502.	4.0	7
70	Influenza Vaccination and Treatment with Antiviral Agents Among Hospitalized Adults in the 2014–2015 and 2015–2016 Influenza Seasons. Open Forum Infectious Diseases, 2017, 4, S316-S317.	0.9	0
71	Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses. PLoS Pathogens, 2017, 13, e1006194.	4.7	90
72	Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012–2013. Clinical Infectious Diseases, 2016, 62, civ952.	5.8	30

#	Article	IF	CITATIONS
73	Next-Generation Sequencing of Influenza Viruses in a Household Cohort Accurately Identifies Transmission Pairs and Reveals a Bottleneck Size of Close to One. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
74	Community-Acquired Pneumonia in Adults Hospitalized With Acute Respiratory Illness During the 2014–2015 Influenza Season: Participant Characteristics and Viral Etiologies. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
75	Influenza Antiviral Use Among High-Risk Outpatients During Four Recent Influenza Seasons—United States, 2011–2015. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
76	No Evidence of Influenza Vaccine Effectiveness Against Antigenically Drifted Influenza A (H3N2) Viruses in a Household Cohort During the 2014–2015 Influenza Season. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
77	Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014–2015. Journal of Infectious Diseases, 2016, 214, 1010-1019.	4.0	101
78	2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clinical Infectious Diseases, 2016, 63, 1564-1573.	5.8	229
79	Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains. Journal of Infectious Diseases, 2016, 214, 1947-1951.	4.0	55
80	Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics, 2016, 137, e20153279.	2.1	80
81	Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013–2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated. Journal of Infectious Diseases, 2016, 213, 1229-1236.	4.0	50
82	Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013–2014 in the United States. Journal of Infectious Diseases, 2016, 213, 1546-1556.	4.0	159
83	Oseltamivir for influenza – Authors' reply. Lancet, The, 2016, 387, 125.	13.7	0
84	Oseltamivir for influenza – Authors' reply. Lancet, The, 2015, 386, 1135-1136.	13.7	6
85	Use of Influenza Antiviral Medications Among Outpatients at High Risk for Influenza-Associated Complications During the 2013–2014 Influenza Season. Clinical Infectious Diseases, 2015, 60, 1677-1680.	5.8	21
86	The Effect of Reactive School Closure on Community Influenza-Like Illness Counts in the State of Michigan During the 2009 H1N1 Pandemic. Clinical Infectious Diseases, 2015, 60, e90-e97.	5.8	28
87	How should influenza be treated? Focus on antivirals. Vaccine, 2015, 33, 7033-7036.	3.8	0
88	Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet, The, 2015, 385, 1729-1737.	13.7	461
89	Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination. Journal of Infectious Diseases, 2015, 212, 1914-1922.	4.0	99
90	Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. Journal of Infectious Diseases, 2015, 212, 1191-1199.	4.0	251

#	Article	IF	CITATIONS
91	Influenza Vaccine Effectiveness in Households With Children During the 2012-2013 Season: Assessments of Prior Vaccination and Serologic Susceptibility. Journal of Infectious Diseases, 2015, 211, 1519-1528.	4.0	88
92	Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. Vaccine, 2015, 33, 5181-5187.	3.8	14
93	533Persistence of Antibody to Influenza Hemagglutinin over Two Influenza Seasons. Open Forum Infectious Diseases, 2014, 1, S19-S19.	0.9	0
94	535Effectiveness of Seasonal Influenza Vaccines against Influenza A(H1N1)pdm09 Illness during Three Influenza Seasons, US Flu VE Network. Open Forum Infectious Diseases, 2014, 1, S20-S20.	0.9	0
95	1139Risk of influenza after Previous Acute Respiratory Illness in a Cohort of Households with Children. Open Forum Infectious Diseases, 2014, 1, S338-S338.	0.9	0
96	Use of Influenza Antiviral Agents by Ambulatory Care Clinicians During the 2012-2013 Influenza Season. Clinical Infectious Diseases, 2014, 59, 774-782.	5.8	53
97	Factors associated with influenza vaccine receipt in community dwelling adults and their children. Vaccine, 2014, 32, 1841-1847.	3.8	68
98	Frequency of Acute Respiratory Illnesses and Circulation of Respiratory Viruses in Households With Children Over 3 Surveillance Seasons. Journal of Infectious Diseases, 2014, 210, 1792-1799.	4.0	88
99	Current research on respiratory viral infections: XIII International Symposium on Respiratory Viral Infections: part 2. Future Virology, 2011, 6, 1283-1288.	1.8	0
100	Current research on respiratory viral infections: XIII International Symposium on Respiratory Viral Infections: part 1. Future Virology, 2011, 6, 1155-1160.	1.8	0
101	Seasonal influenza vaccinations: specialized products for different target groups. Vaccine, 2010, 28, D14-D23.	3.8	5
102	Seasonal influenza and vaccination coverage. Vaccine, 2010, 28, D33-D44.	3.8	71
103	Seasonal influenza vaccines: evolutions and future trends. Expert Review of Vaccines, 2009, 8, 383-389.	4.4	21
104	Comparative Efficacy of Inactivated and Live Attenuated Influenza Vaccines. New England Journal of Medicine, 2009, 361, 1260-1267.	27.0	250
105	Influenza control in the 21st century: Optimizing protection of older adults. Vaccine, 2009, 27, 5043-5053.	3.8	111
106	Epidemiology of influenza. Vaccine, 2008, 26, D45-D48.	3.8	95
107	Seasonal and Pandemic Influenza: A 2007 Update on Challenges and Solutions. Clinical Infectious Diseases, 2008, 46, 1024-1031.	5.8	31
108	Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use. Antimicrobial Agents and Chemotherapy, 2006, 50, 2395-2402.	3.2	333

#	Article	IF	CITATIONS
109	Vaccines and Antiviral Drugs in Pandemic Preparedness. Emerging Infectious Diseases, 2006, 12, 55-60.	4.3	110
110	The Threat of an Avian Influenza Pandemic. New England Journal of Medicine, 2005, 352, 323-325.	27.0	112
111	Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses. Antiviral Therapy, 2005, 10, 873-877.	1.0	55
112	Detection and Control of Influenza Outbreaks in Well-Vaccinated Nursing Home Populations. Clinical Infectious Diseases, 2004, 39, 459-464.	5.8	110
113	Occurrence of respiratory virus: time, place and person. Pediatric Infectious Disease Journal, 2004, 23, S58-S64.	2.0	113